Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors
The chymotrypsin-like (ChT-L) activity is one of the key regulators of intracellular protein degradation. Elevated proteasome ChT-L activity has recently been reported in plasma of patients with leukemia and myelodysplastic syndrome and suggested to have a prognostic significance. The aim of the pre...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2011-08, Vol.32 (4), p.753-759 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 759 |
|---|---|
| container_issue | 4 |
| container_start_page | 753 |
| container_title | Tumor biology |
| container_volume | 32 |
| creator | Hempel, Dominika Wojtukiewicz, Marek Z. Kozłowski, Leszek Romatowski, Jacek Ostrowska, Halina |
| description | The chymotrypsin-like (ChT-L) activity is one of the key regulators of intracellular protein degradation. Elevated proteasome ChT-L activity has recently been reported in plasma of patients with leukemia and myelodysplastic syndrome and suggested to have a prognostic significance. The aim of the present study was to evaluate plasma proteasome ChT-L activity in patients with newly diagnosed solid tumors at early and advanced stages of the disease. The activity was assayed using the fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC, in a cohort of 155 patients with early/advanced rectal (
n
= 43/29), gastric (
n
= 6/13), and breast (
n
= 37/27) cancer and compared with that in normal individuals (
n
= 55). The median plasma proteasome ChT-L activity was elevated by 20–32% in patients with advanced stage of rectal, gastric, and breast cancer compared with healthy donors. The difference turned out to be statistically significant (
P
|
| doi_str_mv | 10.1007/s13277-011-0177-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_875723761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>875723761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-9d8fa58e3d83aba66ecc6d3ba1afbea334fbd327319f5877f4b82aefd1e5edd23</originalsourceid><addsrcrecordid>eNp1kE1LHTEUhoNUql77A7opoZuuxuYkdya5yyJtFQQ3upRwJjmjsfPVJKPcf99crrUgdBFySJ685-Rh7COIMxBCf02gpNaVACirFPKAHcNaqkooI96VWoCo1tKoI3aS0qMQUG82zXt2JKEB0KY5ZneXo4uEiTyfe0wD8jlOuRxMA3H3sB2mHLdzCmPVh1_E0eXwFPKWh5HPmAONOfHnkB84-iccXYlJUx88z8swxXTKDjvsE3142Vfs9sf3m_OL6ur65-X5t6vKKS1ytfGmw9qQ8kZhi01DzjVetQjYtYRKrbvWl68q2HS10bpbt0YidR6oJu-lWrEv-9wy_O-FUrZDSI76HkealmSNrrVUuoFCfn5DPk5LHMtwO6gWjSy6Vgz2kItTSpE6O8cwYNxaEHZn3u7N22Le7szb3QifXoKXdiD_-uKv6gLIPZDK1XhP8V_n_6f-AVu1kNc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>875506228</pqid></control><display><type>article</type><title>Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hempel, Dominika ; Wojtukiewicz, Marek Z. ; Kozłowski, Leszek ; Romatowski, Jacek ; Ostrowska, Halina</creator><creatorcontrib>Hempel, Dominika ; Wojtukiewicz, Marek Z. ; Kozłowski, Leszek ; Romatowski, Jacek ; Ostrowska, Halina</creatorcontrib><description>The chymotrypsin-like (ChT-L) activity is one of the key regulators of intracellular protein degradation. Elevated proteasome ChT-L activity has recently been reported in plasma of patients with leukemia and myelodysplastic syndrome and suggested to have a prognostic significance. The aim of the present study was to evaluate plasma proteasome ChT-L activity in patients with newly diagnosed solid tumors at early and advanced stages of the disease. The activity was assayed using the fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC, in a cohort of 155 patients with early/advanced rectal (
n
= 43/29), gastric (
n
= 6/13), and breast (
n
= 37/27) cancer and compared with that in normal individuals (
n
= 55). The median plasma proteasome ChT-L activity was elevated by 20–32% in patients with advanced stage of rectal, gastric, and breast cancer compared with healthy donors. The difference turned out to be statistically significant (
P
< 0.001). By contrast, values in patients with early stage of malignancies were not significantly different from those observed in normal individuals. We also found that plasma proteasome activity correlated with serum carcinoembryonic antigen levels in the group of patients with rectal cancer (
r
= 0.433,
P
< 0.05). Elevated plasma proteasome ChT-L activity is indicative of advanced stage of rectal, gastric, and breast cancer. However, the activity does not seem to be a parameter with clinically relevant potential in terms of early detection of cancer in this subset of patients.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-011-0177-2</identifier><identifier>PMID: 21611786</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Blotting, Western ; Breast Neoplasms - blood ; Breast Neoplasms - pathology ; Cancer ; Cancer Research ; Carcinoembryonic Antigen - blood ; Chymases - blood ; Enzymes ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Proteasome Endopeptidase Complex - blood ; Rectal Neoplasms - blood ; Rectal Neoplasms - pathology ; Research Article ; Stomach Neoplasms - blood ; Stomach Neoplasms - pathology</subject><ispartof>Tumor biology, 2011-08, Vol.32 (4), p.753-759</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-9d8fa58e3d83aba66ecc6d3ba1afbea334fbd327319f5877f4b82aefd1e5edd23</citedby><cites>FETCH-LOGICAL-c370t-9d8fa58e3d83aba66ecc6d3ba1afbea334fbd327319f5877f4b82aefd1e5edd23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-011-0177-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-011-0177-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21611786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hempel, Dominika</creatorcontrib><creatorcontrib>Wojtukiewicz, Marek Z.</creatorcontrib><creatorcontrib>Kozłowski, Leszek</creatorcontrib><creatorcontrib>Romatowski, Jacek</creatorcontrib><creatorcontrib>Ostrowska, Halina</creatorcontrib><title>Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>The chymotrypsin-like (ChT-L) activity is one of the key regulators of intracellular protein degradation. Elevated proteasome ChT-L activity has recently been reported in plasma of patients with leukemia and myelodysplastic syndrome and suggested to have a prognostic significance. The aim of the present study was to evaluate plasma proteasome ChT-L activity in patients with newly diagnosed solid tumors at early and advanced stages of the disease. The activity was assayed using the fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC, in a cohort of 155 patients with early/advanced rectal (
n
= 43/29), gastric (
n
= 6/13), and breast (
n
= 37/27) cancer and compared with that in normal individuals (
n
= 55). The median plasma proteasome ChT-L activity was elevated by 20–32% in patients with advanced stage of rectal, gastric, and breast cancer compared with healthy donors. The difference turned out to be statistically significant (
P
< 0.001). By contrast, values in patients with early stage of malignancies were not significantly different from those observed in normal individuals. We also found that plasma proteasome activity correlated with serum carcinoembryonic antigen levels in the group of patients with rectal cancer (
r
= 0.433,
P
< 0.05). Elevated plasma proteasome ChT-L activity is indicative of advanced stage of rectal, gastric, and breast cancer. However, the activity does not seem to be a parameter with clinically relevant potential in terms of early detection of cancer in this subset of patients.</description><subject>Adult</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blotting, Western</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Chymases - blood</subject><subject>Enzymes</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Proteasome Endopeptidase Complex - blood</subject><subject>Rectal Neoplasms - blood</subject><subject>Rectal Neoplasms - pathology</subject><subject>Research Article</subject><subject>Stomach Neoplasms - blood</subject><subject>Stomach Neoplasms - pathology</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1LHTEUhoNUql77A7opoZuuxuYkdya5yyJtFQQ3upRwJjmjsfPVJKPcf99crrUgdBFySJ685-Rh7COIMxBCf02gpNaVACirFPKAHcNaqkooI96VWoCo1tKoI3aS0qMQUG82zXt2JKEB0KY5ZneXo4uEiTyfe0wD8jlOuRxMA3H3sB2mHLdzCmPVh1_E0eXwFPKWh5HPmAONOfHnkB84-iccXYlJUx88z8swxXTKDjvsE3142Vfs9sf3m_OL6ur65-X5t6vKKS1ytfGmw9qQ8kZhi01DzjVetQjYtYRKrbvWl68q2HS10bpbt0YidR6oJu-lWrEv-9wy_O-FUrZDSI76HkealmSNrrVUuoFCfn5DPk5LHMtwO6gWjSy6Vgz2kItTSpE6O8cwYNxaEHZn3u7N22Le7szb3QifXoKXdiD_-uKv6gLIPZDK1XhP8V_n_6f-AVu1kNc</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Hempel, Dominika</creator><creator>Wojtukiewicz, Marek Z.</creator><creator>Kozłowski, Leszek</creator><creator>Romatowski, Jacek</creator><creator>Ostrowska, Halina</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110801</creationdate><title>Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors</title><author>Hempel, Dominika ; Wojtukiewicz, Marek Z. ; Kozłowski, Leszek ; Romatowski, Jacek ; Ostrowska, Halina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-9d8fa58e3d83aba66ecc6d3ba1afbea334fbd327319f5877f4b82aefd1e5edd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blotting, Western</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Chymases - blood</topic><topic>Enzymes</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Proteasome Endopeptidase Complex - blood</topic><topic>Rectal Neoplasms - blood</topic><topic>Rectal Neoplasms - pathology</topic><topic>Research Article</topic><topic>Stomach Neoplasms - blood</topic><topic>Stomach Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hempel, Dominika</creatorcontrib><creatorcontrib>Wojtukiewicz, Marek Z.</creatorcontrib><creatorcontrib>Kozłowski, Leszek</creatorcontrib><creatorcontrib>Romatowski, Jacek</creatorcontrib><creatorcontrib>Ostrowska, Halina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hempel, Dominika</au><au>Wojtukiewicz, Marek Z.</au><au>Kozłowski, Leszek</au><au>Romatowski, Jacek</au><au>Ostrowska, Halina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>32</volume><issue>4</issue><spage>753</spage><epage>759</epage><pages>753-759</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>The chymotrypsin-like (ChT-L) activity is one of the key regulators of intracellular protein degradation. Elevated proteasome ChT-L activity has recently been reported in plasma of patients with leukemia and myelodysplastic syndrome and suggested to have a prognostic significance. The aim of the present study was to evaluate plasma proteasome ChT-L activity in patients with newly diagnosed solid tumors at early and advanced stages of the disease. The activity was assayed using the fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC, in a cohort of 155 patients with early/advanced rectal (
n
= 43/29), gastric (
n
= 6/13), and breast (
n
= 37/27) cancer and compared with that in normal individuals (
n
= 55). The median plasma proteasome ChT-L activity was elevated by 20–32% in patients with advanced stage of rectal, gastric, and breast cancer compared with healthy donors. The difference turned out to be statistically significant (
P
< 0.001). By contrast, values in patients with early stage of malignancies were not significantly different from those observed in normal individuals. We also found that plasma proteasome activity correlated with serum carcinoembryonic antigen levels in the group of patients with rectal cancer (
r
= 0.433,
P
< 0.05). Elevated plasma proteasome ChT-L activity is indicative of advanced stage of rectal, gastric, and breast cancer. However, the activity does not seem to be a parameter with clinically relevant potential in terms of early detection of cancer in this subset of patients.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>21611786</pmid><doi>10.1007/s13277-011-0177-2</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2011-08, Vol.32 (4), p.753-759 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_875723761 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Blotting, Western Breast Neoplasms - blood Breast Neoplasms - pathology Cancer Cancer Research Carcinoembryonic Antigen - blood Chymases - blood Enzymes Female Humans Middle Aged Neoplasm Staging Proteasome Endopeptidase Complex - blood Rectal Neoplasms - blood Rectal Neoplasms - pathology Research Article Stomach Neoplasms - blood Stomach Neoplasms - pathology |
| title | Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20plasma%20proteasome%20chymotrypsin-like%20activity%20in%20patients%20with%20advanced%20solid%20tumors&rft.jtitle=Tumor%20biology&rft.au=Hempel,%20Dominika&rft.date=2011-08-01&rft.volume=32&rft.issue=4&rft.spage=753&rft.epage=759&rft.pages=753-759&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-011-0177-2&rft_dat=%3Cproquest_cross%3E875723761%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=875506228&rft_id=info:pmid/21611786&rfr_iscdi=true |